High nuclear karyopherin 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy

Modern Pathology

Volumn 27, Issue 1, 2014, Pages 96-106

  Grupp, Katharina ^a,b   Habermann, Mareike ^b   Sirma, Hüseyin ^b   Simon, Ronald ^b   Steurer, Stefan ^b   Hube Magg, Claudia ^b   Prien, Kristina ^b   Burkhardt, Lia ^b   Jedrzejewska, Karolina ^b   Salomon, Georg ^c   Heinzer, Hans ^c   Wilczak, Waldemar ^b   Kluth, Martina ^b   Izbicki, Jakob R ^a   Sauter, Guido ^b   Minner, Sarah ^b   Schlomm, Thorsten ^b,c   Tsourlakis, Maria Christina ^b  

^a Visceral and Thoracic Surgery Department and Clinic   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Prostate Cancer Center   (Germany)

Author keywords

3p13; 5q21; 6q15; KPNA2; prostate cancer; PTEN; tissue microarray

Indexed keywords

KARYOPHERIN ALPHA; KARYOPHERIN ALPHA2; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; FEMALE; FOLLOW UP; GENE DELETION; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MIDDLE AGED; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; TISSUE MICROARRAY;

AGED; ALPHA KARYOPHERINS; CELL NUCLEUS; CHROMOSOME DELETION; GENE DELETION; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; KALLIKREINS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; TIME FACTORS; TISSUE ARRAY ANALYSIS; TRANS-ACTIVATORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84891736053     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.127     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Nakielny S, Dreyfuss G. Transport of proteins and RNAs in and out of the nucleus. Cell 1999;99: 677-690. (Pubitemid 30017639)
3. Teng SC, Wu KJ, Tseng SF, et al. Importin KPNA2, NBS1, DNA repair and tumorigenesis. J Mol Histol 2006;37:293-299.
4. Mortezavi A, Hermanns T, Seifert HH, et al. KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res 2011;17:1111-1121.
5. Noetzel E, Rose M, Bornemann J, et al. Nuclear transport receptor karyopherin-alpha2 promotes malignant breast cancer phenotypes in vitro. Oncogene 2012;31:2101-2114.
6. Umegaki N, Tamai K, Nakano H, et al. Differential regulation of karyopherin alpha 2 expression by TGFbeta1 and IFN-gamma in normal human epidermal keratinocytes: evident contribution of KPNA2 for nuclear translocation of IRF-1. J Invest Dermatol 2007;127:1456-1464. (Pubitemid 46762977)
7. Wang CI, Wang CL, Wang CW, et al. Importin subunit alpha-2 is identified as a potential biomarker for nonsmall cell lung cancer by integration of the cancer cell secretome and tissue transcriptome. Int J Cancer 2011;128:2364-2372.
8. Gluz O, Wild P, Meiler R, et al. Nuclear karyopherin alpha2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity. Int J Cancer 2008;123:1433-1438.
9. Winnepenninckx V, Lazar V, Michiels S, et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 2006;98:472-482.
10. Zheng M, Tang L, Huang L, et al. Overexpression of karyopherin-2 in epithelial ovarian cancer and correlation with poor prognosis. Obstet Gynecol 2010;116:884-891.
11. Gousias K, Becker AJ, Simon M, et al. Nuclear karyopherin a2: a novel biomarker for infiltrative astrocytomas. J Neurooncol 2012;109:545-553.
12. Lapointe J, Li C, Giacomini CP, et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 2007;67:8504-8510. (Pubitemid 47437424)
13. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
14. Berger MF, Lawrence MS, Demichelis F, et al. The genomic complexity of primary human prostate cancer. Nature 2011;470:214-220.
15. Kluth M, Hesse J, Heinl A, et al. Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Mod Pathol 2013;26:975-983.
16. Burkhardt L, Fuchs S, Krohn A, et al. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res 2013;73:2795-2805.
17. Krohn A, Diedler T, Burkhardt L, et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusionnegative prostate cancer. Am J Pathol 2012;181:401-412.
18. Huang S, Gulzar ZG, Salari K, et al. Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness. Oncogene 2012;31:4164-4170.
19. Liu S, Yoshimoto M, Trpkov K, et al. Detection of ERG gene rearrangements and PTEN deletions in unsuspected prostate cancer of the transition zone. Cancer Biol Ther 2011;11:562-566.
20. Schlomm T, Iwers L, Kirstein P, et al. Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol 2008;21:1371-1378.
21. Mirlacher M, Simon R. Recipient block TMA technique. Methods Mol Biol 2010;664:37-44.
22. Minner S, Enodien M, Sirma H, et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res 2011;17:5878-5888.
23. Minner S, Wittmer C, Graefen M, et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 2011;71:281-288.
24. Grupp K, Kohl S, Sirma H, et al. Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence. Mod Pathol 2013; 26:733-742.
25. Muller J, Ehlers A, Burkhardt L, et al. Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers. Int J Cancer 2013;132:1333-1340.
26. Bubendorf L, Sauter G, Moch H, et al. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 1996;178:437-441. (Pubitemid 26145136)
27. El Gammal AT, Bruchmann M, Zustin J, et al. Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer. Clin Cancer Res 2010;16:56-64.
28. Rubin MA, Dunn R, Strawderman M, et al. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Pathol 2002;26: 312-319. (Pubitemid 34184454)
29. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001;159:2249-2256. (Pubitemid 33104278)
30. Tennstedt P, Koster P, Bruchmann A, et al. The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers. Int J Oncol 2012;40:261-268.
31. Minner S, Gartner M, Freudenthaler F, et al. Marked heterogeneity of ERG expression in large primary prostate cancers. Mod Pathol 2013;26:106-116.
32. Wise AM, Stamey TA, McNeal JE, et al. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 2002;60: 264-269. (Pubitemid 34831770)
33. Epstein JI, Feng Z, Trock BJ, et al. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 2012;61:1019-1024.
34. Cutress ML, Whitaker HC, Mills IG, et al. Structural basis for the nuclear import of the human androgen receptor. J Cell Sci 2008;121:957-968. (Pubitemid 351639415)
35. Kim IS, Kim DH, Han SM, et al. Truncated form of importin alpha identified in breast cancer cell inhibits nuclear import of p53. J Biol Chem 2000;275: 23139-23145.
36. Li S, Ku CY, Farmer AA, et al. Identification of a novel cytoplasmic protein that specifically binds to nuclear localization signal motifs. J Biol Chem 1998;273: 6183-6189. (Pubitemid 28144702)
37. Nadler SG, Tritschler D, Haffar OK, et al. Differential expression and sequence-specific interaction of karyopherin alpha with nuclear localization sequences. J Biol Chem 1997;272:4310-4315. (Pubitemid 27078503)
38. Yuen HF, Chan KK, Grills C, et al. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways. Clin Cancer Res 2012;18:380-391.
39. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-648. (Pubitemid 41528150)
40. Brase JC, Johannes M, Mannsperger H, et al. TMPRSS2-ERG-specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-beta signaling. BMC Cancer 2011;11:507.
41. Gupta S, Iljin K, Sara H, et al. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelialto-mesenchymal transition in human prostate cancer cells. Cancer Res 2010;70:6735-6745.
42. Hermans KG, Boormans JL, Gasi D, et al. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clin Cancer Res 2009;15:6398-6403.
43. Tomlins SA, Laxman B, Varambally S, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008;10:177-188. (Pubitemid 351240884)
44. Jhavar S, Brewer D, Edwards S, et al. Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU Int 2009;103:1256-1269.
45. Cadigan KM, Peifer M. Wnt signaling from development to disease: insights from model systems. Cold Spring Harb Perspect Biol 2009;1:a002881.
46. Schmierer B, Hill CS. TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 2007;8:970-982. (Pubitemid 350174642)
47. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998;273:13375-13378. (Pubitemid 28268370)
48. Ly TK, Wang J, Pereira R, et al. Activation of the Ran GTPase is subject to growth factor regulation and can give rise to cellular transformation. J Biol Chem 2010; 285:5815-5826.
49. Radisavljevic ZM, Gonzalez-Flecha B. TOR kinase and Ran are downstream from PI3K/Akt in H2O2-induced mitosis. J Cell Biochem 2004;91:1293-1300.
50. Carver BS, Tran J, Gopalan A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009;41: 619-624.